These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 16784654)

  • 1. [Clinicopathological significance of aberrant methylation of the fragile histidine triad gene in patients with hepatocellular carcinoma].
    Sun Y; Geng XP; Zhu LX; Xiong QR; Qian YB; Dong GY; Li XM
    Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):609-12. PubMed ID: 16784654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alterations of the fragile histidine triad gene in hepatitis C virus-associated hepatocellular carcinoma.
    Zekri AR; Bahnassy AA; Hafez M; El-Shehaby AM; Sherif GM; Khaled HM; Zakhary N
    J Gastroenterol Hepatol; 2005 Jan; 20(1):87-94. PubMed ID: 15610452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
    Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
    Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant methylation of Fragile Histidine Triad gene is associated with poor prognosis in early stage esophageal squamous cell carcinoma.
    Lee EJ; Lee BB; Kim JW; Shim YM; Hoseok I; Han J; Cho EY; Park J; Kim DH
    Eur J Cancer; 2006 May; 42(7):972-80. PubMed ID: 16564166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome.
    Lin J; Yao DM; Qian J; Wang YL; Han LX; Jiang YW; Fei X; Cen JN; Chen ZX
    Leuk Res; 2008 Oct; 32(10):1541-5. PubMed ID: 18367246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
    Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis.
    Gramantieri L; Chieco P; Di Tomaso M; Masi L; Piscaglia F; Brillanti S; Gaiani S; Valgimigli M; Mazziotti A; Bolondi L
    Clin Cancer Res; 1999 Nov; 5(11):3468-75. PubMed ID: 10589760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced acetylated histone H4 is associated with promoter methylation of the fragile histidine triad gene in resected esophageal squamous cell carcinoma.
    Tzao C; Sun GH; Tung HJ; Hsu HS; Hsu WH; Wang YC; Cheng YL; Lee SC
    Ann Thorac Surg; 2006 Aug; 82(2):396-401; discussion 401. PubMed ID: 16863736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent silencing of fragile histidine triad gene (FHIT) in Burkitt's lymphoma is associated with aberrant hypermethylation.
    Hussain A; Gutiérrez MI; Timson G; Siraj AK; Deambrogi C; Al-Rasheed M; Gaidano G; Magrath I; Bhatia K
    Genes Chromosomes Cancer; 2004 Dec; 41(4):321-9. PubMed ID: 15384174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
    Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
    Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with multiple myeloma.
    Takada S; Morita K; Hayashi K; Matsushima T; Sawamura M; Murakami H; Nojima Y
    Eur J Haematol; 2005 Dec; 75(6):505-10. PubMed ID: 16313263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas.
    Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG
    Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5'CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer.
    Tzao C; Tsai HY; Chen JT; Chen CY; Wang YC
    Eur J Cancer; 2004 Sep; 40(14):2175-83. PubMed ID: 15341994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Correlation between methylation of 5'-CpG islands and inactivation of FHIT gene in cervical cancer].
    Shi HR; Wu QH; Suo ZH; Nesland JM
    Ai Zheng; 2005 Jan; 24(1):7-11. PubMed ID: 15642192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypermethylation of FHIT as a prognostic marker in nonsmall cell lung carcinoma.
    Maruyama R; Sugio K; Yoshino I; Maehara Y; Gazdar AF
    Cancer; 2004 Apr; 100(7):1472-7. PubMed ID: 15042681
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
    Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
    Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FHIT expression and hypermethylation in esophageal squamous cell carcinoma.
    Noguchi T; Takeno S; Kimura Y; Uchida Y; Daa T; Yokoyama S; Gabbert HE; Mueller W
    Int J Mol Med; 2003 Apr; 11(4):441-7. PubMed ID: 12632095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of DNA methyltransferase 3b on FHIT expression and DNA methylation of the FHIT promoter region in hepatoma SMMC-7721 cells.
    Wang JX; Zhang YG; Zhao LS
    Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):273-7. PubMed ID: 19502167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological significance of aberrant methylation of RARbeta2 at 3p24, RASSF1A at 3p21.3, and FHIT at 3p14.2 in patients with non-small cell lung cancer.
    Tomizawa Y; Iijima H; Nomoto T; Iwasaki Y; Otani Y; Tsuchiya S; Saito R; Dobashi K; Nakajima T; Mori M
    Lung Cancer; 2004 Dec; 46(3):305-12. PubMed ID: 15541815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Relationship between aberrant FHIT transcripts and hepatocellular carcinoma].
    Yu YC; Sun FY; Li Z; Lu SY; Teng XH
    Zhonghua Gan Zang Bing Za Zhi; 2003 Sep; 11(9):550-1. PubMed ID: 14552718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.